Palatin Technologies (NYSE American: PTN) stands at a pivotal moment in its corporate journey, with multiple data readouts expected in the first quarter of 2025 that could significantly transform the company’s trajectory in the increasingly valuable obesity treatment market.
Key Catalysts Approaching
The company recently completed its Phase 2 clinical study evaluating the co-administration of melanocortin-4 receptor (MC4R) agonist bremelanotide with tirzepatide (GLP-1/GIP) for obesity treatment. With the database lock now completed, topline results are expected before the end of the quarter. With just 4 trading days left until the end of Q1, these announcements are anticipated imminently.
Simultaneously, Palatin is preparing to release data from its Phase 2 study of PL8177, an oral MC1R agonist for ulcerative colitis. Patient enrollment has been completed, with results also expected in Q1 2025.
Targeting the Obesity Market Through Melanocortin Pathways
Palatin’s strategic focus on obesity positions it in a rapidly expanding market projected to grow from approximately $5 billion in 2023 to $44 billion by 2030. The company’s approach leverages the central leptin-melanocortin pathway, which plays a critical role in regulating food intake and energy balance.
“The MC4R pathway helps control eating and how our bodies use energy,” explained Carl Spana, Ph.D., President and CEO of Palatin. “We believe that MC4R agonists, especially the long-acting peptides and oral small molecules we are developing, could be an important way to treat obesity, manage weight loss, and help with rare conditions like hypothalamic obesity.”
Palatin’s obesity portfolio includes:
- Bremelanotide, which is already FDA-approved as Vyleesi® for another indication
- A novel once-weekly peptide MC4R agonist
- PL7737, an oral small molecule MC4R agonist
Addressing Limitations of Current Obesity Treatments
What makes Palatin’s approach particularly compelling is its potential to address the limitations of existing GLP-1 receptor agonist therapies. While medications like tirzepatide can drive substantial weight loss, challenges include high discontinuation rates due to side effects (67% according to company reports), weight loss plateaus after the first year, and significant weight regain when treatment stops.
Palatin believes MC4R agonists could counter the physiological adaptations that favor weight regain and potentially enhance long-term weight maintenance. The company’s focus on oral formulations also provides a significant advantage in a market currently dominated by injectable therapies.
Ulcerative Colitis Program
The company’s PL8177 program for ulcerative colitis represents another significant opportunity. The global ulcerative colitis treatment market is substantial and growing, with projections indicating it will reach $15.81 billion by 2034, reflecting a CAGR of 4.1%. Palatin’s melanocortin-based approach offers a novel mechanism that could potentially provide efficacy without the safety concerns associated with current immunosuppressive therapies.
According to one Wall Street analyst covering Palatin, the company has received a Buy rating with a price target of $7.00, suggesting significant confidence in the potential of these upcoming data readouts.
Recent Palatin Technologies News Highlights:
- Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
- Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
- Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This article is published by Wall Street Wire a promotional content brand network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution is paid promotional content related to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to.
